Hjem › T-celle-lymfom › North Carolina
T-celle-lymfom kliniske forsøg i North Carolina
6 studier for T-celle-lymfom søger deltagere på steder i North Carolina.
Byer i North Carolina
Officiel studietekst (engelsk)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Wake Forest University Health Sciences, Winston-Salem
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- North Carolina Cancer Hospital, Chapel Hill
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- og 15 flere
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 14. sep. 2026 · NCT06724237Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Novant Health Presbyterian Hemby Children's Hospital, Charlotte
RekruttererFase 2
Alder 1 til 18 · Alle køn · Opdateret 10. aug. 2026 · NCT06390319MB-105 in Patients With CD5 Positive T-cell Lymphoma
- University of North Carolina at Chapel Hill, Chapel Hill
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 3. okt. 2025 · NCT06534060Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Carolina-Levine Children's Hospital, Charlotte
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.